This pill allows you to have anxiety-free sex. So why aren't more people taking it? - Video

Acceptability of Three Novel HIV Prevention Methods among Young Male and Transgender Female Sex Workers in Puerto Rico

Sex workers need HIV-prevention methods they can control and incorporate easily in their work. We studied the acceptability of three methods: HIV self-test use with clients, oral pre-exposure prophylaxis (PrEP), and rectal microbicide gel. 

Four male and eight transgender female (TGF) sex workers in Puerto Rico completed a baseline survey with a quantitative measure of likelihood of use. From them, one male and four TGF also completed a 12-week study of rectal microbicide placebo gel use prior to receptive anal intercourse with male clients and evaluated via qualitative in-depth interviews and follow-up quantitative assessments how each method could be incorporated into their work. 

Most were interested in a rectal microbicide gel and able to use it covertly with clients. Challenges to using the HIV self-test with clients included the potential for both breach of confidentiality and confronting violent situations. Participants also expressed interest in oral PrEP, but raised concerns about side effects.

Purchase full article at:   http://goo.gl/sQKdS3

By:  Giguere R1, Frasca T2, Dolezal C2, Febo I3, Cranston RD4, Mayer K5, McGowan I4, Carballo-Diéguez A2.

• 1Division of Gender, Sexuality and Health, HIV Center for Clinical and Behavioral Studies, Columbia University and NY State Psychiatric Institute, 1051 Riverside Drive, Unit 15, New York, NY, 10032, USA. giguere@nyspi.columbia.edu.
• 2Division of Gender, Sexuality and Health, HIV Center for Clinical and Behavioral Studies, Columbia University and NY State Psychiatric Institute, 1051 Riverside Drive, Unit 15, New York, NY, 10032, USA.
• 3Department of Pediatrics, Gama Project, University of Puerto Rico Medical Sciences Campus, San Juan, PR, USA.
• 4School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
• 5Fenway Health, Fenway Institute, Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA.
• AIDS Behav. 2016 Apr 5. 

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health

HIV-negative male couples' attitudes about pre-exposure prophylaxis (PrEP) and using PrEP with a sexual agreement

One efficacious strategy to help prevent HIV is oral pre-exposure prophylaxis (PrEP), a daily regimen of antiretroviral treatment taken by HIV-negative individuals. Two of the recommendations of Centers for Disease Control and Prevention (CDC) guidelines for PrEP pertain to being in a relationship (i.e., male couples). 

Despite the recognition of how primary partners in male couples' relationships shape HIV risk and CDC's PrEP guidelines, there is a paucity of data that examine HIV-negative male couples' attitudes toward PrEP use and using PrEP with a sexual agreement. A sexual agreement is an explicit agreement made between two individuals about what sex and other related behaviors may occur within and outside of their relationship. In this qualitative study, we examine HIV-negative male couples' attitudes toward PrEP use and whether they thought PrEP could be integrated into a sexual agreement. 

Data for this study are drawn from couple-level interviews conducted in 2014 with 29 HIV-negative male couples who had a sexual agreement and were from Atlanta or Detroit. Both passive (e.g., flyers) and active (e.g., targeted Facebook advertisements) recruitment methods were used; the sample was stratified by agreement type. Thematic analysis was applied to identify the following themes regarding HIV-negative male couples' attitudes toward PrEP use: 

1. PrEP and condom use; 
2. concerns about PrEP (e.g., effectiveness, side effects, and promoting sexually risky behavior); and 
3. accessibility of PrEP. 

Some thought PrEP could be a part of couples' agreement because it could help reduce sexual anxiety and sexual risk, and would help keep the couple safe. Others described PrEP use with an agreement as something for "others". Some were also concerned that incorporating PrEP could usurp the need for a sexual agreement in a couples' relationship. 

These themes highlight the need to improve informational messaging and promotion efforts about PrEP among HIV-negative male couples who may benefit from using it.

Purchase full article at:   http://goo.gl/aTkxGz

By:  Mitchell JW1, Lee JY1, Woodyatt C2, Bauermeister J3, Sullivan P2, Stephenson R4.

• 1 Department of Public Health Sciences , University of Miami Miller School of Medicine , Miami , FL , USA.
• 2 Department of Epidemiology, Rollins School of Public Health , Emory University , Atlanta , GA , USA.
• 3 Department of Health Behavior and Health Education, School of Public Health, and The Center for Sexuality and Health Disparities , University of Michigan , Ann Arbor , MI , USA.
• 4 Department of Health Behavior and Biological Sciences, School of Nursing, and The Center for Sexuality and Health Disparities , University of Michigan , Ann Arbor , MI , USA.
• AIDS Care. 2016 Apr 7:1-6. 

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health

Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers

Highlights

• To achieve the same impact on FSW HIV prevalence as increasing condom use by 1%, the coverage of PrEP has to increase by >2%.
• The relative impact of PrEP compared to condoms increases for scenarios where pimps contribute to HIV transmission.
• Condom promotion interventions should remain the mainstay HIV prevention strategy for FSWs.
• PrEP should only be implemented to fill prevention gaps where condoms cannot be used.

In many settings, interventions targeting female sex workers (FSWs) could significantly reduce the overall transmission of HIV. To understand the role HIV pre-exposure prophylaxis (PrEP) could play in controlling HIV transmission amongst FSWs, it is important to understand how its impact compares with scaling-up condom use-one of the proven HIV prevention strategies for FSWs. 

It is important to remember that condoms also have other benefits such as reducing the incidence of sexually transmitted infections and preventing pregnancy. A dynamic deterministic model of HIV transmission amongst FSWs, their clients and other male partners (termed 'pimps') was used to compare the protection provided by PrEP for HIV-negative FSWs with FSWs increasing their condom use with clients and/or pimps. For different HIV prevalence scenarios, levels of pimp interaction, and baseline condom use, we estimated the coverage of PrEP that gives the same reduction in endemic FSW HIV prevalence or HIV infections averted as different increases in condom use. 

To achieve the same impact on FSW HIV prevalence as increasing condom use by 1%, the coverage of PrEP has to increase by >2%. The relative impact of PrEP increases for scenarios where pimps contribute to HIV transmission, but not greatly, and decreases with higher baseline condom use. In terms of HIV infections averted over 10 years, the relative impact of PrEP compared to condoms was reduced, with a >3% increase in PrEP coverage achieving the same impact as a 1% increase in condom use. 

Condom promotion interventions should remain the mainstay HIV prevention strategy for FSWs, with PrEP only being implemented once condom interventions have been maximised or to fill prevention gaps where condoms cannot be used.

Below:  The relative impact of PrEP compared to condoms for decreasing the endemic FSW HIV prevalence (a) or averting HIV infections (b) after 10 years for different baseline FSW HIV prevalences, with no condom or PrEP use at baseline.

Below:  Sensitivity analysis on how the relative impact of PrEP changes for specific changes in model parameters

Full article at:   http://goo.gl/hsnL86

By:  Mukandavire Z1, Mitchell KM2, Vickerman P3.

• 1Social and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: Zindoga.Mukandavire@lshtm.ac.uk.
• 2Department of Infectious Disease Epidemiology, Imperial College London, London, UK. Electronic address: Kate.Mitchell@imperial.ac.uk.
• 3School of Social and Community Medicine, University of Bristol, Bristol, UK. Electronic address: Peter.Vickerman@bristol.ac.uk. 
• Epidemics. 2016 Mar;14:62-70. doi: 10.1016/j.epidem.2015.10.002. Epub 2015 Nov 12.

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health

Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.

We sought to determine preferences for oral versus long-acting injectable (LAI) PrEP among gay and bisexual men (GBM). We surveyed a national U.S. sample of 1071 GBM about forms of PrEP. 

LAI PrEP was found to be acceptable among 43.2 % of men when injected monthly compared with 53.6 % of men when injected every 3 months. When asked to choose between forms of PrEP, 46.0 % preferred LAI, 14.3 % oral, 21.7 % whichever was most effective, 10.1 % had no preference, and 7.8 % would not take PrEP. There were no differences in PrEP preferences by race/ethnicity, income, region of residence, or relationship status. 

Those unwilling to take PrEP were significantly older than those who preferred LAI PrEP and those who would take either. Those who preferred the most effective form were younger, had less education, and reported more recent club drug use. Those who reported condomless anal sex and those who thought they were good PrEP candidates were more willing to take PrEP. Long-term health and side effects were of the greatest concern for both LAI and oral PrEP. The availability of LAI PrEP has the potential to increase uptake among GBM. 

The results of ongoing clinical trials of LAI PrEP will need to demonstrate similar or greater efficacy as daily Truvada for uptake to be maximized.

Purchase full article at:   http://goo.gl/XrfjA6

By:  Parsons JT1,2,3, Rendina HJ4, Whitfield TH4,5, Grov C4,6.

• 1Center for HIV/AIDS Educational Studies & Training, Hunter College of the City University of New York (CUNY), New York, NY, USA. jeffrey.parsons@hunter.cuny.edu.
• 2Health Psychology and Clinical Sciences Doctoral Program, The Graduate Center of the City University of New York (CUNY), New York, NY, USA. jeffrey.parsons@hunter.cuny.edu.
• 3Department of Psychology, Hunter College of the City University of New York (CUNY), 695 Park Ave., New York, NY, 10065, USA. jeffrey.parsons@hunter.cuny.edu.
• 4Center for HIV/AIDS Educational Studies & Training, Hunter College of the City University of New York (CUNY), New York, NY, USA.
• 5Health Psychology and Clinical Sciences Doctoral Program, The Graduate Center of the City University of New York (CUNY), New York, NY, USA.
• 6CUNY Graduate School of Public Health and Health Policy, New York, NY, USA. 
• AIDS Behav. 2016 Mar 21. 

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health

The Role of Psychiatrists in HIV Prevention

Via:  http://goo.gl/Gg5hGd

PrEP Adherence Patterns Strongly Impact Individual HIV Risk & Observed Efficacy in Randomized Clinical Trials

BACKGROUND:

Randomized controlled trials (RCT) suggest that the efficacy of tenofovir-based pre-exposure prophylaxis (PrEP) strongly depends on consistency of PrEP use. We explore how patterns of pill-taking and waning of PrEP protection may affect PrEP efficacy for HIV prevention.

METHODS:

A two-arm RCT was simulated by mathematical models assuming that prescribed daily doses were skipped periodically, randomly or in large blocks. Risk-driven adherence, in which PrEP was taken when sex was expected, was also investigated. Three temporal PrEP protection profiles were explored: long (5 days), intermediate (3 days) and short (24 hours). Modeling results were compared to the efficacy observed in completed RCTs.

RESULTS:

Expected PrEP efficacy was 60% with periodic, 50% with random and 34% with block adherence when PrEP had a long protection profile and pills were taken only 50% of the days. Risk-driven pill-taking resulted in 29% and 37% daily pills taken and efficacy of 43% and 51% for long protection. High PrEP efficacy comparable with that observed in Partners PrEP and CDC Botswana trials was simulated under long protection, high overall adherence and limited block pill-taking; the moderate efficacy observed in iPrEx and Bangkok trials was comparable with the 50% adherence scenarios under random pill-taking and long protection.

CONCLUSIONS:

Pill-taking patterns may have a substantial impact on the protection provided by PrEP even when the same numbers of pills are taken. When PrEP retains protection for longer than a day, pill-taking patterns can explain a broad range of efficacies observed in PrEP RCTs.

Purchase full article at:   http://goo.gl/ucgzmR

By:  Dimitrov DT1, MÂsse BR, Donnell D.

• 1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center and Department of Applied Mathematics, University of Washington, Seattle, Washington, USA 
• 2 Sainte-Justine Research Centre, University of Montreal, Montreal, Quebec, Canada 
• 3 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center and Department of Global Health, University of Washington, Seattle, Washington, USA.
• J Acquir Immune Defic Syndr. 2016 Mar 16. 

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health

PrEP as Peri-Conception HIV Prevention for Women and Men

Daily oral tenofovir (TDF)-based pre-exposure prophylaxis (PrEP) is an effective HIV prevention strategy and recommended for men and women with substantial risk of HIV acquisition. 

The peri-conception period, the stage prior to pregnancy when condom use is necessarily reduced, has elevated HIV risk that can be mitigated by PrEP use. Data from a randomized trial suggest that peri-conception PrEP use by HIV-seronegative women does not increase the risk of pregnancy loss, birth defects or congenital anomalies, preterm birth, or infant growth faltering. 

Women considering PrEP use throughout pregnancy must weigh the known increased risk of HIV acquisition with unknown risks of drug effects on infant growth. PrEP has been used safely by HIV-seronegative men with HIV-seropositive female partners who have become pregnant. 

As an effective user-controlled HIV prevention strategy, PrEP offers autonomy and empowerment for HIV prevention and can be recommended alongside antiretroviral therapy, fertility screening, vaginal self-insemination, intercourse timed to peak fertility, medically assisted reproduction, and other safer conception strategies to provide multiple options. 

The integration of PrEP into safer conception programs is warranted and will safely reduce HIV transmission to women, men, and children during the peri-conception period.

Purchase full article at:   http://goo.gl/WG4DZc

By:  Heffron R1, Pintye J2, Matthews LT3, Weber S4, Mugo N5.

• 1Departments of Global Health and Epidemiology, University of Washington, 325 Ninth Avenue, Box 359927, Seattle, WA, 98104, USA. rheffron@uw.edu.
• 2School of Nursing, University of Washington, 325 Ninth Avenue, Box 359909, Seattle, WA, 98104, USA.
• 3Division of Infectious Disease and Center for Global Health, Massachusetts General Hospital, 125 Nashua Street, Suite 722, Boston, MA, 02114, USA.
• 4University of California San Francisco, 1001 Potrero Ave, 6D-33, San Francisco, CA, 94110, USA.
• 5Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya. 
• Curr HIV/AIDS Rep. 2016 Mar 18. 

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health

HIV Incidence among Men Who Have Sex with Men After Diagnosis with Sexually Transmitted Infections

BACKGROUND:

Men who have sex with men (MSM) are at high risk for acquiring HIV infection after diagnosis with other sexually transmitted infections (STIs). Identifying the STIs associated with the greatest risk of subsequent HIV infection could help target prevention interventions, particularly preexposure prophylaxis (PrEP).

METHODS:

Using matched HIV and STI surveillance data from Washington State from January 1, 2007, to June 30, 2013, we calculated the incidence of new HIV diagnoses after different STI diagnoses among MSM. Men entered observation at the time of their first STI diagnosis during the study period and exited at HIV diagnosis or June 30, 2013. Cox proportional hazards regression was used to conduct a global comparison of rates.

RESULTS:

From January 1, 2007, to June 30, 2013, 6577 HIV-negative MSM were diagnosed as having 10,080 bacterial STIs at 8371 unique time points and followed for 17,419 person-years. Two hundred eighty (4.3%) men were subsequently diagnosed as having HIV infection for an overall incidence of 1.6 per 100 person-years (95% confidence interval, 1.4-1.8). The estimated incidence of HIV diagnoses among all MSM in the state was 0.4 per 100 person-years. Men who have sex with men were at the greatest risk for HIV diagnosis after being diagnosed as having rectal gonorrhea (HIV incidence, 4.1 per 100 person-years), followed by early syphilis (2.8), urethral gonorrhea (1.6), rectal chlamydial infection (1.6), pharyngeal gonorrhea (1.1), late syphilis (1.0), and urethral chlamydial infection (0.6; P < 0.0001 overall).

CONCLUSIONS:

Men who have sex with men diagnosed as having rectal gonorrhea and early syphilis were at the greatest risk for being diagnosed as having HIV infection after STI diagnosis. These men should be prioritized for more intensive prevention interventions, including PrEP.

Below:  Cumulative hazard of HIV diagnosis following bacterial STIs (STI) GC = gonorrhea. CT = chlamydial infection

Below:  Percent of 736 MSM newly diagnosed as having HIV infection from July 2011 to June 2013 with a reported STI diagnosis in the 2 years before HIV diagnosis GC indicates gonorrhea; CT, chlamydial infection.

Full article at:   http://goo.gl/N3Kb5L

By:  Katz DA1, Dombrowski JC, Bell TR, Kerani RP, Golden MR.

• 1From the Departments of *Medicine and †Epidemiology, University of Washington, Seattle, WA; ‡HIV/STD Program, Public Health-Seattle & King County, Seattle, WA; and §Infectious Disease Assessment Unit, Washington State Department of Health, Olympia, WA. 
• Sex Transm Dis. 2016 Apr;43(4):249-54. doi: 10.1097/OLQ.0000000000000423.

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health

Acceptability & Willingness to Use HIV Pre-Exposure Prophylaxis among HIV-Negative Men Who Have Sex with Men in Switzerland

Pre-exposure prophylaxis (PrEP) is discussed as an additional HIV prevention method targeting men who have sex with men (MSM). So far, PrEP has not been approved in Switzerland and only little is known about the acceptability of PrEP among MSM living in Switzerland. Given the slow uptake of PrEP among MSM in the USA, the objectives of the study were to investigate the acceptability for PrEP and to identify factors influencing the acceptability for this prevention method and the willingness to adopt it. 

During a 4-month period we conducted five focus group discussions with 23 consecutively sampled HIV-negative MSM aged 22-60 years living in Switzerland. We analyzed the data according to qualitative content analysis. The acceptability of PrEP varied considerably among the participants. 

Some would use PrEP immediately after its introduction in Switzerland because it provides an alternative to condoms which they are unable or unwilling to use. Others were more ambivalent towards PrEP but still considered it 

1. an additional or alternative protection to regular condom use, 
2. an option to engage in sexual activities with less worries and anxieties or 
3. a protection during receptive anal intercourse independently of the sexual partner's protective behaviour. 

Some participants would not consider using PrEP at all: they do not see any benefit in PrEP as they have adopted safer sex practices and did not mention any problems with condom use. Others are still undecided and could imagine using an improved form of PrEP. The results provide a valuable basis for a model explaining the acceptability of PrEP among MSM and suggest including the personal HIV protection strategy in the considerations adopted.

Full article at:   http://goo.gl/Bjn9An

By:   Gredig D1, Uggowitzer F1, Hassler B1, Weber P1, Nideröst S1.

• 1 School of Social Work , University of Applied Sciences and Arts Northwestern Switzerland , Olten , Switzerland. 
• AIDS Care. 2016 Mar 13:1-4.

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health

Beyond Condoms: Risk Reduction Strategies among Gay, Bisexual & Other Men Who Have Sex with Men Receiving Rapid HIV Testing in Montreal, Canada

Gay, bisexual, and other men who have sex with men (MSM) have adapted their sexual practices over the course of the HIV/AIDS epidemic based on available data and knowledge about HIV. This study sought to identify and compare patterns in condom use among gay, bisexual, and other MSM who were tested for HIV at a community-based testing site in Montreal, Canada. 

Results showed that while study participants use condoms to a certain extent with HIV-positive partners and partners of unknown HIV status, they also make use of various other strategies such as adjusting to a partner's presumed or known HIV status and viral load, avoiding certain types of partners, taking PEP, and getting tested for HIV. 

These findings suggest that MSM who use condoms less systematically are not necessarily taking fewer precautions but may instead be combining or replacing condom use with other approaches to risk reduction.

Full PDF article at:   http://goo.gl/HuCkMf

By:  Otis J1,2, McFadyen A3, Haig T3,4,5, Blais M3, Cox J6, Brenner B7, Rousseau R8, Émond G9, Roger M10, Wainberg M7; Spot Study Group.

• 1Department of Sexology, Université du Québec à Montréal, Case postale 8888, succursale Centre-ville, Montreal, QC, H3C 3P8, Canada. otis.joanne@uqam.ca.
• 2CIHR Canadian HIV Trials Network, Vancouver, Canada. otis.joanne@uqam.ca.
• 3Department of Sexology, Université du Québec à Montréal, Case postale 8888, succursale Centre-ville, Montreal, QC, H3C 3P8, Canada.
• 4CIHR Canadian HIV Trials Network, Vancouver, Canada.
• 5COCQ-SIDA, Montreal, QC, Canada.
• 6Direction de santé publique du CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, QC, Canada.
• 7Faculty of Medicine, McGill University, Montreal, QC, Canada.
• 8RÉZO, Montreal, QC, Canada.
• 9Applied Human Sciences, Concordia University, Montreal, QC, Canada.
• 10Laboratoire de Biologie Moléculaire, Centre hospitalier de l'université de Montréal, Montreal, QC, Canada. 
• AIDS Behav. 2016 Mar 9

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health

Engaging Black Men Who Have Sex with Men (BMSM) in Los Angeles in HIV Pre-Exposure Prophylaxis (PrEP) - Video

More at:    http://goo.gl/Tsf5Yu

Uptake of PrEP and Condom and Sexual Risk Behavior among MSM During the ANRS IPERGAY Trial

The double-blind phase of the randomized ANRS IPERGAY trial, evaluating sexual activity-based oral HIV pre-exposure prophylaxis (PrEP), was conducted among high-risk men who have sex with men (MSM). 

Results showed an 86% (95% CI: 40-98) relative reduction in HIV incidence among participants with tenofovir disoproxil fumarate-emtricitabine vs. placebo. The present pooled analysis aimed to analyze (i) participants' adherence to the prescribed treatment and/or condom use during sexual intercourse and (ii) sexual behavior during the double-blind phase of the study. Four hundred MSM were enrolled in the trial. Every 2 months they completed online questionnaires collecting sexual behavior and PrEP adherence data regarding their most recent sexual intercourse. A total of 2232 questionnaires (M0-M24) were analyzed. Changes over time were evaluated using a mixed model accounting for multiple measures. 

Irrespective of sexual partner and practice type, on average, 

• 42.6% (min: 32.1-max: 45.8%) reported PrEP use only during their most recent episode of sexual intercourse; 
• 29% (22.9 - 35.6%) reported both PrEP and condom use; 
• 11.7% (7.2 - 18.9%) reported condom-use only, and 
• 16.7% (10.8 - 29.6%) reported no PrEP or condom use with no significant change during the study. 
• Scheduled (i.e., correct) PrEP use was reported on average by 59.0% (47.2  -68.5%) of those reporting PrEP use during their most recent sexual intercourse. 
• Overall, 70.3% (65.3 - 79.4%) and 69.3% (58.3 - 75.4%) of participants reported, respectively, condomless anal and condomless receptive anal intercourse during their most recent sexual encounter without significant change during follow-up. 

Overall, on average 83.3% (min: 70.4-max: 89.2%) of participants protected themselves by PrEP intake or condom use or both during the trial, and no increase in at-risk sexual practices was observed. 

None of these indicators showed significant trend during the follow-up, although we found a tendency toward decrease (p = .19) of the median number of sexual partners strengthening the absence of behavioral disinhibition. 

On-demand PrEP within a comprehensive HIV prevention package could improve prevention in MSM.

Purchase full article at:   http://goo.gl/rOmWSi

By:  Sagaon-Teyssier L1,2,3, Suzan-Monti M1,2,3, Demoulin B1,2,3, Capitant C4, Lorente N1,5, Préau M1,6, Mora M1,2,3, Rojas Castro D6,7, Chidiac C8, Chas J9,Meyer L4, Molina JM10, Spire B1,2,3; ANRS IPERGAY Study Group.

• 1 INSERM, UMR912 (SESSTIM) , Marseille , France.
• 2 Aix Marseille Université, UMR_S912, IRD , Marseille , France.
• 3 ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur , Marseille , France.
• 4 Inserm SC10 , Villejuif , France.
• 5 Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agència de Salut Pública de Catalunya (ASPC) , Badalona , Spain.
• 6 GRePS Lyon 2 Université , Bron , France.
• 7 AIDES (Mission Innovation Recherche Expérimentation) , Pantin , France.
• 8 Department of Infectious Diseases , Hôpital de la Croix Rousse, INSERM U1052 , Lyon , France.
• 9 Department of Infectious Diseases , Hôpital Tenon , Paris , France.
• 10 Department of Infectious Disease , Assistance Publique Hôpitaux de Paris, University of Paris Diderot Paris 7, INSERM U941 , Paris , France.
• AIDS Care. 2016 Feb 17:1-8. 

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health